✦ LIBER ✦

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

✍ Scribed by Albertella, M. R.; Loadman, P. M.; Jones, P. H.; Phillips, R. M.; Rampling, R.; Burnet, N.; Alcock, C.; Anthoney, A.; Vjaters, E.; Dunk, C. R.; Harris, P. A.; Wong, A.; Lalani, A. S.; Twelves, C. J.

Book ID: 118009059
Publisher: American Association for Cancer Research
Year: 2008
Tongue: English
Weight: 694 KB
Volume: 14
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-07-4020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

261 POSTER Banoxantrone (AQ4N), a tissue

261 POSTER Banoxantrone (AQ4N), a tissue CYP 450 targeted prodrug: the results of a Phase I study using an accelerated dose escalation in patients with advanced solid tumors

✍ J. Sarantopoulos; A.W. Tolcher; A. Wong; G. Goel; M. Beeram; G. Lam; K. Desai; K 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 128 KB

A phase I trial of PR-104, a nitrogen mu

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

✍ Michael B. Jameson; Danny Rischin; Mark Pegram; John Gutheil; Adam V. Patterson; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 303 KB

Phase I Study of Oral Gemcitabine Prodru

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

✍ Koolen, S. L. W.; Witteveen, P. O.; Jansen, R. S.; Langenberg, M. H. G.; Kroneme 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 378 KB

389 POSTER Phase I study of the ribosome

389 POSTER Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors

✍ I. Duran; L.L. Siu; C. Kollmannsberger; L. Gontovnick; S. Leong; L. Wang; C. Bra 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

472 A phase I study of IMGN388, an antib

472 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors

✍ J. Bendell; K. Moore; A. Qin; D. Johnson; J. Schindler; K. Papadopoulos; A.W. To 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Safety and pharmacokinetics of high-dose

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study

✍ Mitchell E. Gross; Lawrence Leichman; Elizabeth S. Lowe; Alan Swaisland; David B 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 432 KB